Effects of serum amyloid a and lysophosphatidylcholine on intracellular calcium concentration in human coronary artery smooth muscle cells

International Heart Journal

Volumn 52, Issue 3, 2011, Pages 185-193

  Tanaka, Tomofumi ^a   Ikeda, Kenichi ^a   Yamamoto, Yumiko ^a   Iida, Haruko ^a   Kikuchi, Hironobu ^a   Morita, Toshihiro ^a   Yamasoba, Tatsuya ^a   Nagai, Ryozo ^a   Nakajima, Toshiaki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Fura 2 am; GTP binding protein; Human coronary arterial smooth muscle cells; Lysophosphatidylcholine; Serum amyloid a; Transient receptor potential; TRPM7

Indexed keywords

CALCIUM ION; GUANINE NUCLEOTIDE BINDING PROTEIN; LYSOPHOSPHATIDYLCHOLINE; MAGNESIUM ION; MESSENGER RNA; SERUM AMYLOID A; TRANSIENT RECEPTOR POTENTIAL CHANNEL 1; TRANSIENT RECEPTOR POTENTIAL CHANNEL 3; TRANSIENT RECEPTOR POTENTIAL CHANNEL 4; TRANSIENT RECEPTOR POTENTIAL CHANNEL 5; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; TRANSIENT RECEPTOR POTENTIAL CHANNEL 7; TRANSIENT RECEPTOR POTENTIAL CHANNEL M1; TRANSIENT RECEPTOR POTENTIAL CHANNEL M2; TRANSIENT RECEPTOR POTENTIAL CHANNEL M3; TRANSIENT RECEPTOR POTENTIAL CHANNEL M4; TRANSIENT RECEPTOR POTENTIAL CHANNEL M7; TRANSIENT RECEPTOR POTENTIAL CHANNEL M8; UNINDEXED DRUG; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 2; VANILLOID RECEPTOR 3; VANILLOID RECEPTOR 4; VANILLOID RECEPTOR 5; VANILLOID RECEPTOR 6;

ARTERY MUSCLE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CALCIUM SIGNALING; CALCIUM TRANSPORT; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY ATHEROSCLEROSIS; GENE EXPRESSION; HUMAN; HUMAN CELL; LIPID BLOOD LEVEL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER;

CALCIUM; CALCIUM CHANNEL BLOCKERS; CELLS, CULTURED; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRENES; HUMANS; LYSOPHOSPHATIDYLCHOLINES; MAGNESIUM; MYOCYTES, SMOOTH MUSCLE; PERTUSSIS TOXIN; PYRROLIDINONES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERUM AMYLOID A PROTEIN; TRPC CATION CHANNELS;

EID: 79958699196     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.52.185     Document Type: Article

References (66)

1. O'Brien KD, Chait A. Serum amyloid A: the "other" infammatory protein. Curr Atheroscler Rep 2006; 8: 62-8. (Review)
2. Brissette L, Young I, Narindrasorasak S, Kisilevsky R, Deeley R. Differential induction of the serum amyloid A gene family in response to an infammatory agent and to amyloid-enhancing factor. J Biol Chem 1989; 264: 19327-32.
3. Meek RL, Urieli-Shoval S, Benditt EP. Expression of apolipopro-tein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proc Natl Acad Sci USA 1994; 91: 3186-90.
4. Badolato R, Wang JM, Murphy WJ, et al. Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infl-tration of monocytes and polymorphonuclear leukocytes. J Exp Med 1994; 180: 203-9.
5. Leinonen E, Hurt-Camejo E, Wiklund O, Hultén LM, Hiukka A, Taskinen MR. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis 2003; 166: 387-94.
6. Tannock LP, O'Brien KD, Knopp RH, et al. Cholesterol feeding increases C-reactive protein and serum amyloid A levels in lean insulin-sensitive subjects. Circulation 2005; 111: 3058-62.
7. Johnson BD, Kip KE, Marroquin OC, et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004; 109: 726-32.
8. Wang X, Chai H, Wang Z, Lin PH, Yao Q, Chen C. Serum amyloid A induces endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells. Am J Physiol Circ Physiol 2008; 295: H2399-H2408.
9. Kumon Y, Hosokawa T, Suehiro T, Ikeda Y, Sipe JD, Hashimoto K. Acute-phase, but not constitutive serum amyloid A (SAA) is chemotactic for cultured human aortic smooth muscle cells. Amyloid 2002; 9: 237-41.
10. Matsumoto T, Kobayashi T, Kamata K. Role of lysophosphatidyl-choline (LPC) in atherosclerosis. Curr Med Chem 2007; 14: 3209-20. (Review)
11. Kugiyama K, Sakamoto T, Misumi I, et al. Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells. Circ Res 1993; 73: 335-43.
12. Xu Y. Sphingosylphosphorylcholine and lysophosphatidylcholine: G protein-coupled receptors and receptor-mediated signal trans-duction. Biochim Biophys Acta 2002; 1582: 81-8. (Review)
13. Sonoki K, Iwase M, Iino K, et al. Atherogenic role of lysophos-phatidylcholine in low-density lipoprotein modifed by phospholi-pase A2 and in diabetic patients: protection by nitric oxide donor. Metabolism 2003; 52: 308-14.
14. Zhang B, Fan P, Shimoji E, et al. Modulating effects of cholesterol feeding and simvastatin treatment on platelet-activating factor acetylhydrolase activity and lysophosphatidylcholine concentration. Atherosclerosis 2006; 186: 291-301.
15. Galili O, Versari D, Sattler KJ, et al. Early experimental obesity is associated with coronary endothelial dysfunction and oxidative stress. Am J Physiol Heart Circ Physiol 2007; 292: H904-H911.
16. Wells IC, Peitzmeier G, Vincent JK. Lecithin: cholesterol acyl-transferase and lysolecithin in coronary atherosclerosis. Exp Mol Pathol 1986; 45: 303-10.
17. Portman OW, Soltys P, Alexander M, Osuga T. Metabolism of lys-olecithin in vivo: effects of hyperlipemia and atherosclerosis in squirrel monkeys. J Lipid Res 1970; 11: 596-604.
18. Vidaver GA, Ting A, Lee JW. Evidence that lysolecithin is an important causal agent of atherosclerosis. J Theor Biol 1985; 115: 27-41.
19. Bergmann SR, Ferguson TB Jr, Sobel BE. Effects of amphiphiles on erythrocytes, coronary arteries, and perfused hearts. Am J Physiol 1981; 240: H229-37.
20. Flavahan NA. Atherosclerosis or lipoprotein-induced endothelial dysfunction. Potential mechanisms underlying reduction in EDRF/ nitric oxide activity. Circulation 1992; 85: 1927-38. (Review)
21. Chai YC, Howe PH, DiCorleto PE, Chisolm GM. Oxidized low density lipoprotein and lysophosphatidylcholine stimulate cell cycle entry in vascular smooth muscle cells. Evidence for release of fbroblast growth factor-2. J Biol Chem 1996; 271: 17791-7.
22. Chang MY, Tsoi C, Wight TN, Chait A. Lysophosphatidylcholine regulates synthesis of biglycan and the proteoglycan form of mac-rophage colony stimulating factor. Arterioscler Thromb Vasc Biol 2003; 23: 809-15.
23. Scalia R, Murohara T, Campbell B, Kaji A, Lefer AM. Lysophos-phatidylcholine stimulates leukocyte rolling and adherence in rat mesenteric microvasculature. Am J Physiol 1997; 272: H2584-H2590.
24. Takahara N, Kashiwagi A, Maegawa H, Shigeta Y. Lysophosphati-dylcholine stimulates the expression and production of MCP-1 by human vascular endothelial cells. Metabolism 1996; 45: 559-64.
25. Kohno M, Yokokawa K, Yasunari K, et al. Induction by lysophos-phatidylcholine, a major phospholipid component of atherogenic lipoproteins, of human coronary artery smooth muscle cell migration. Circulation 1998; 98: 353-9.
26. Hsieh CC, Yen MH, Liu HW, Lau YT. Lysophosphatidylcholine induces apoptotic and non-apoptotic death in vascular smooth muscle cells: in comparison with oxidized LDL. Atherosclerosis 2000; 151: 481-91.
27. Badolato R, Johnston JA, Wang JM, et al. Serum amyloid A induces calcium mobilization and chemotaxis of human monocytes by activating a pertussis toxin-sensitive signaling pathway. J Immunol 1995; 155: 4004-10.
28. 2+ channel. Am J Respir Cell Mol Biol 2007; 36: 585-93.
29. 2+ infux induced by dimethylphytosphingosine and lysophosphatidylcho-line in U937 monocytes. Biochem Biophys Res Commun 2006; 348: 1116-22.
30. Terasawa K, Nakajima T, Iida H, et al. Nonselective cation currents regulate membrane potential of rabbit coronary arterial cell: modulation by lysophosphatidylcholine. Circulation 2002; 106: 3111-9.
31. Minke B, Cook B. TRP channel proteins and signal transduction. Physiol Rev 2002; 82: 429-72. (Review)
32. Montell C, Birnbaumer L, Flockerzi V. The TRP channels, a remarkably functional family. Cell 2002; 108: 595-8. (Review)
33. Clapham DE. TRP channels as cellular sensors. Nature 2003; 426: 517-24. (Review)
34. Flemming PK, Dedman AM, Xu SZ, et al. Sensing of lysophos-pholipids by TRPC5 calcium channel. J Biol Chem 2006; 281: 4977-82.
35. So I, Chae MR, Kim SJ, Lee SW. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces the change of calcium mobilization via TRPC ion channels in cultured human corporal smooth muscle cells. Int J Impot Res 2005; 17: 475-83.
36. Schilling T, Eder C. Non-selective cation channel activity is required for lysophosphatidylcholine-induced monocyte migration. J Cell Physiol 2009; 221: 325-34.
37. Monet M, Gkika D, Lehen'kyi V, et al. Lysophospholipids stimulate prostate cancer cell migration via TRPV2 channel activation. Biochim Biophys Acta 2009; 1793: 528-39.
38. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440-50.
39. Nakajima T, Okuda Y, Chisaki K, et al. Bile acids increase intrac-ellular Ca(2+) concentration and nitric oxide production in vascular endothelial cells. Br J Pharmacol 2000; 130: 1457-67.
40. Kishida S, Nakajima T, Ma J, et al. Amiodarone and N-desethyl-amiodarone enhance endothelial nitric oxide production in human endothelial cells. Int Heart J 2006; 47: 85-93.
41. 2+ transporter transient receptor potential melastatin 7 (TRPM7) cation channel by bradykinin in vascular smooth muscle cells. J Hy-pertens 2009; 27: 155-66.
42. McFadzean I, Gibson A. The developing relationship between receptor-operated and store-operated calcium channels in smooth muscle. Br J Pharmacol 2002; 135: 1-13. (Review)
43. Yip H, Chan WY, Leung PC, et al. Expression of TRPC homologs in endothelial cells and smooth muscle layers of human arteries. Histochem Cell Biol 2004; 122: 553-61.
44. Takahashi Y, Watanabe H, Murakami M, et al. Involvement of transient receptor potential canonical 1 (TRPC1) in angiotensin II-induced vascular smooth muscle cell hypertrophy. Atherosclerosis 2007; 195: 287-96.
45. BjÖrkman L, Karlsson J, Karlsson A, et al. Serum amyloid A mediates human neutrophil production of reactive oxygen species through a receptor independent of formyl peptide receptor like-1. J Leukoc Biol 2008; 83: 245-53.
46. He R, Sang H, Ye RD. Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. Blood 2003; 101: 1572-81.
47. Lee H Y, Kim SD, Shim JW, et al. A pertussis toxin sensitive G-protein-independent pathway is involved in serum amyloid A-in-duced formyl peptide receptor 2-mediated CCL2 production. Exp Mol Med 2010; 42: 302-9.
48. 2+ currents in rat aortic smooth muscle cells in primary culture. Circ Res 1996; 79: 14-9.
49. Hu HZ, Gu Q, Wang C, et al. 2-aminoethoxydiphenyl borate is a common activator of TRPV1, TRPV2, and TRPV3. J Biol Chem 2004; 279: 35741-8.
50. Watanabe H, Davis JB, Smart D, et al. Activation of TRPV4 channels (hVRL-2/mTRP12) by phorbol derivatives. J Biol Chem 2002; 277: 13569-77.
51. Delmas P. Assembly and gating of TRPC channels in signalling microdomains. Novartis Found Symp 2004; 258: 75-89.
52. Obukhov AG, Nowycky MC. TRPC4 can be activated by G-pro-tein-coupled receptors and provides sufficient Ca(2+) to trigger exocytosis in neuroendocrine cells. J Biol Chem 2002; 277: 16172-8.
53. Jeon J P, Lee KP, Park EJ, et al. The specifc activation of TRPC4 by Gi protein subtype. Biochem Biophys Res Commun 2008; 377: 538-43.
54. Schaefer M, Plant TD, Obukhov AG, Hofmann T, Gudermann T, Schultz G. Receptor-mediated regulation of the nonselective cation channels TRPC4 and TRPC5. J Biol Chem 2000; 275: 17517-26.
55. Kisilevsky R. Serum amyloid A (SAA), a protein without a function: some suggestions with reference to cholesterol metabolism. Med Hypotheses 1991; 35: 337-41.
56. Boulay G, Brown DM, Qin N, et al. Modulation of Ca(2+) entry by polypeptides of the inositol 1,4,5-trisphosphate receptor (IP3R) that bind transient receptor potential (TRP): evidence for roles of TRP and IP3R in store depletion-activated Ca(2+) entry. Proc Natl Acad Sci USA 1999; 96: 14955-60.
57. Hofmann T, Obukhov AG, Schaefer M, Harteneck C, Gudermann T, Schultz G. Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. Nature 1999; 397: 259-63.
58. Okada T, Inoue R, Yamazaki K, et al. Molecular and functional characterization of a novel mouse transient receptor potential protein homologue TRP7. Ca(2+) -permeable cation channel that is constitutively activated and enhanced by stimulation of G protein-coupled receptor. J Biol Chem 1999; 274: 27359-70.
59. 2+-independent phospholipase A2-dependent gating of TRPM8 by lysophospholi-pids. J Biol Chem 2006; 281: 40174-82.
60. Venkatachalam K, Zheng F, Gill DL. Regulation of canonical transient receptor potential (TRPC) channel function by diacyl-glycerol and protein kinase C. J Biol Chem 2003; 278: 29031-40.
61. Andersson DA, Nash M, Bevan S. Modulation of the cold-activated channel TRPM8 by lysophospholipids and polyunsaturated fatty acids. J Neurosci 2007; 27: 3347-55.
62. 2+ homeostasis by TRPM7. Cell 2003; 114: 191-200.
63. Schultz DR, Arnold PI. Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycopro-tein, and fibrinogen. Semin Arthritis Rheum 1990; 20: 129-47. (Review)
64. Rienhoff HY Jr, Huang JH, Li XX, Liao XS. Molecular and cellular biology of serum amyloid A. Mol Biol Med 1990; 7: 287-98. (Review)
65. Corr PB, Snyder DW, Lee BI, Gross RW, Keim CR, Sobel BE. Pathophysiological concentrations of lysophosphatides and the slow response. Am J Physiol 1982; 243: H187-H195.
66. Sullivan CP, Seidl SE, Rich CB, Raymondjean M, Schreiber BM. Secretory phospholipase A2, group IIA is a novel serum amyloid A target gene: activation of smooth muscle cell expression by an interleukin-1 receptor-independent mechanism. J Biol Chem 2010; 285: 565-75.